Michael Byrnes

Chief Financial Officer at Fore Biotherapeutics.

Raised on Fore Biotherapeutics filings

$70.4M

of $109.6M offered across 1 Form D filing

Company

Biotech · Philadelphia, PA

BRAF inhibitor for brain and solid tumors

BRAF inhibitor for brain and solid tumors

Fore Biotherapeutics Form D filings
Filed	Security	Sold of offered	Filing
Jul 14, 2026	Equity	$70.4M/ $109.6M	Form D/A

Also named on Fore Biotherapeutics filings